Concepts (133)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Transplantation | 8 | 2017 | 33 | 1.100 |
Why?
|
| Shock, Cardiogenic | 5 | 2025 | 16 | 0.890 |
Why?
|
| Heart-Assist Devices | 3 | 2024 | 31 | 0.690 |
Why?
|
| Cardiomyopathies | 3 | 2025 | 67 | 0.630 |
Why?
|
| Heart Failure | 8 | 2025 | 728 | 0.510 |
Why?
|
| Cardiology | 3 | 2024 | 104 | 0.500 |
Why?
|
| Hospital Mortality | 4 | 2025 | 197 | 0.330 |
Why?
|
| Registries | 4 | 2025 | 294 | 0.330 |
Why?
|
| Equipment Failure | 1 | 2010 | 25 | 0.320 |
Why?
|
| Bacteremia | 2 | 2022 | 66 | 0.250 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2024 | 28 | 0.220 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2024 | 7 | 0.210 |
Why?
|
| Myocardial Ischemia | 1 | 2025 | 98 | 0.210 |
Why?
|
| Respiratory Insufficiency | 1 | 2024 | 60 | 0.210 |
Why?
|
| Humans | 22 | 2025 | 32284 | 0.190 |
Why?
|
| Hemodynamics | 1 | 2023 | 164 | 0.190 |
Why?
|
| Critical Care | 4 | 2024 | 108 | 0.190 |
Why?
|
| Critical Illness | 1 | 2022 | 87 | 0.180 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2022 | 34 | 0.180 |
Why?
|
| Osteoporosis | 1 | 2002 | 51 | 0.170 |
Why?
|
| Staphylococcal Infections | 1 | 2022 | 79 | 0.170 |
Why?
|
| Tissue Donors | 2 | 2017 | 186 | 0.160 |
Why?
|
| Quality Indicators, Health Care | 1 | 2020 | 62 | 0.160 |
Why?
|
| Coronary Care Units | 3 | 2024 | 6 | 0.150 |
Why?
|
| Plasmapheresis | 1 | 1999 | 11 | 0.150 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 1999 | 24 | 0.150 |
Why?
|
| Antibodies | 1 | 1999 | 56 | 0.150 |
Why?
|
| Preoperative Care | 1 | 1999 | 125 | 0.140 |
Why?
|
| Female | 11 | 2025 | 19947 | 0.130 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2017 | 168 | 0.130 |
Why?
|
| Heart Ventricles | 1 | 2017 | 146 | 0.120 |
Why?
|
| Cooperative Behavior | 1 | 2016 | 83 | 0.120 |
Why?
|
| Palliative Care | 1 | 2016 | 51 | 0.120 |
Why?
|
| Patient Care Team | 1 | 2016 | 124 | 0.110 |
Why?
|
| Middle Aged | 8 | 2025 | 11853 | 0.110 |
Why?
|
| Cachexia | 1 | 2015 | 7 | 0.110 |
Why?
|
| Malnutrition | 1 | 2015 | 21 | 0.110 |
Why?
|
| Aged | 6 | 2025 | 10265 | 0.110 |
Why?
|
| Male | 9 | 2025 | 19443 | 0.110 |
Why?
|
| Body Mass Index | 1 | 2017 | 863 | 0.100 |
Why?
|
| Prognosis | 3 | 2024 | 1534 | 0.100 |
Why?
|
| Intensive Care Units | 2 | 2024 | 121 | 0.100 |
Why?
|
| Hospitalization | 1 | 2012 | 475 | 0.070 |
Why?
|
| Depression | 1 | 2012 | 420 | 0.070 |
Why?
|
| United States | 3 | 2024 | 4072 | 0.070 |
Why?
|
| Immunosuppressive Agents | 2 | 2002 | 248 | 0.070 |
Why?
|
| Patient Education as Topic | 1 | 2010 | 245 | 0.070 |
Why?
|
| Retrospective Studies | 4 | 2025 | 3628 | 0.070 |
Why?
|
| Cause of Death | 2 | 2024 | 236 | 0.060 |
Why?
|
| Time Factors | 3 | 2024 | 2205 | 0.050 |
Why?
|
| North America | 1 | 2024 | 31 | 0.050 |
Why?
|
| Graft Rejection | 3 | 2003 | 236 | 0.050 |
Why?
|
| Device Removal | 1 | 2024 | 39 | 0.050 |
Why?
|
| Cardiomyopathy, Restrictive | 1 | 2004 | 2 | 0.050 |
Why?
|
| Chloroquine | 1 | 2004 | 3 | 0.050 |
Why?
|
| Lactates | 1 | 2023 | 2 | 0.050 |
Why?
|
| Antirheumatic Agents | 1 | 2004 | 28 | 0.050 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2004 | 36 | 0.050 |
Why?
|
| Vascular Resistance | 1 | 2023 | 32 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2024 | 110 | 0.050 |
Why?
|
| Hepacivirus | 1 | 2003 | 40 | 0.050 |
Why?
|
| Hepatitis C | 1 | 2003 | 47 | 0.050 |
Why?
|
| Inflammation | 2 | 2015 | 506 | 0.050 |
Why?
|
| Adolescent | 1 | 2010 | 3519 | 0.050 |
Why?
|
| Methicillin | 1 | 2022 | 4 | 0.050 |
Why?
|
| Oxacillin | 1 | 2022 | 5 | 0.050 |
Why?
|
| Calcitonin | 1 | 2002 | 4 | 0.050 |
Why?
|
| Diphosphonates | 1 | 2002 | 9 | 0.050 |
Why?
|
| Survivors | 1 | 2003 | 173 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 312 | 0.040 |
Why?
|
| Staphylococcus aureus | 1 | 2022 | 55 | 0.040 |
Why?
|
| Hormone Replacement Therapy | 1 | 2002 | 94 | 0.040 |
Why?
|
| Bone Density | 1 | 2002 | 169 | 0.040 |
Why?
|
| Quality of Life | 2 | 2017 | 964 | 0.040 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 1999 | 6 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2022 | 324 | 0.040 |
Why?
|
| Immunosuppression | 1 | 1999 | 118 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2024 | 1425 | 0.040 |
Why?
|
| Muromonab-CD3 | 1 | 1997 | 16 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 1999 | 555 | 0.030 |
Why?
|
| Antilymphocyte Serum | 1 | 1997 | 40 | 0.030 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1997 | 9 | 0.030 |
Why?
|
| Myocarditis | 1 | 1997 | 7 | 0.030 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 1997 | 17 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2017 | 133 | 0.030 |
Why?
|
| Advance Care Planning | 1 | 2016 | 15 | 0.030 |
Why?
|
| Ventricular Function, Left | 1 | 2017 | 264 | 0.030 |
Why?
|
| Medicaid | 1 | 2016 | 101 | 0.030 |
Why?
|
| Family | 1 | 2016 | 112 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2016 | 194 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 1997 | 504 | 0.030 |
Why?
|
| Exercise Therapy | 1 | 2017 | 250 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2016 | 137 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2016 | 179 | 0.030 |
Why?
|
| Wasting Syndrome | 1 | 2015 | 14 | 0.030 |
Why?
|
| Appetite | 1 | 2015 | 23 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2016 | 183 | 0.030 |
Why?
|
| Medicare | 1 | 2016 | 219 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 2017 | 363 | 0.030 |
Why?
|
| Nutritional Status | 1 | 2015 | 73 | 0.030 |
Why?
|
| Stroke Volume | 1 | 2017 | 417 | 0.030 |
Why?
|
| Survival Rate | 2 | 2012 | 893 | 0.030 |
Why?
|
| Risk Factors | 1 | 2002 | 3934 | 0.030 |
Why?
|
| Myocardium | 1 | 2015 | 184 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2015 | 215 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2015 | 153 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2012 | 2240 | 0.020 |
Why?
|
| Adult | 3 | 2003 | 9259 | 0.020 |
Why?
|
| Postoperative Complications | 3 | 2003 | 823 | 0.020 |
Why?
|
| Insulin Resistance | 1 | 2015 | 458 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2016 | 2316 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 3902 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 883 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2012 | 1840 | 0.020 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2003 | 7 | 0.010 |
Why?
|
| Illinois | 1 | 2003 | 10 | 0.010 |
Why?
|
| Hypertension, Pulmonary | 1 | 2003 | 22 | 0.010 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2003 | 7 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2003 | 99 | 0.010 |
Why?
|
| Aspartate Aminotransferases | 1 | 2003 | 29 | 0.010 |
Why?
|
| Alkaline Phosphatase | 1 | 2003 | 40 | 0.010 |
Why?
|
| Alanine Transaminase | 1 | 2003 | 47 | 0.010 |
Why?
|
| RNA, Viral | 1 | 2003 | 49 | 0.010 |
Why?
|
| Heart Atria | 1 | 2003 | 81 | 0.010 |
Why?
|
| Cadaver | 1 | 2003 | 151 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2003 | 186 | 0.010 |
Why?
|
| Echocardiography | 1 | 2003 | 190 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2003 | 477 | 0.010 |
Why?
|
| Heart | 1 | 2003 | 177 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2003 | 853 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 1997 | 292 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2003 | 3416 | 0.010 |
Why?
|
| Animals | 1 | 1997 | 8199 | 0.000 |
Why?
|